<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00883727</url>
  </required_header>
  <id_info>
    <org_study_id>SRPL/AMI/07-08/001</org_study_id>
    <nct_id>NCT00883727</nct_id>
  </id_info>
  <brief_title>Ex Vivo Cultured Bone Marrow Derived Allogenic MSCs in AMI</brief_title>
  <official_title>A Randomized, Double Blind, Multicentric, Placebo Controlled, Single Dose, Phase - i/ii Study Assessing the Safety and Efficacy of Intravenous ex Vivo Cultured Adult Allogenic Mesenchymal Stem Cells in Patients With st Elevated Acute Myocardial Infarction (Stemi)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stempeutics Research Pvt Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stempeutics Research Pvt Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial aims to find out the safety and efficacy of adult mesenchymal stem cells
      in patients with myocardial infarction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AE and ECG parameters</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regional myocardial perfusion and infarct size</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stem cell</intervention_name>
    <description>IV infusion of stem cells</description>
    <arm_group_label>stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plasmalyte A</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with STEMI aged between 20 and 70 years, either males or females with
             non-child bearing potential, after 2 days of successful PCI.

          -  Patient has global left ventricular systolic dysfunction with an ejection fraction of
             &lt;50% and &gt;30%.

          -  ECG with sign of acute anterior MI with ST-elevation ≥ 2 mm in at least 2 of the
             following leads I, AVL, V1-V6, or ECG with sign of acute inferoposterior MI with
             ST-elevation ≥1 mm on all of the following leads- II, III, V5-V6 or STelevation ≥ 2 mm
             in at least 2 of the leads.

          -  The target lesion located in the proximal section of the left anterior descending,
             left circumflex or right coronary artery.

          -  Patient with acute myocardial infarction within 10 days prior to IP administration.

          -  Normal liver and renal function.

          -  Able to understand study information provided to him.

          -  Able to give voluntary written consent.

        Exclusion Criteria:

          -  History of acute/chronic inflammatory condition or severe aortic stenosis or
             insufficiency; severe mitral stenosis or severe mitral insufficiency.

          -  Severe co-morbidity associated with a reduction in life expectancy of less than 1
             year.

          -  Advanced renal dysfunction and creatinine ≥ 2mg%.

          -  Advanced hepatic dysfunction.

          -  Have clinically serious and/or unstable intercurrent infection, medical illnesses or
             conditions that are uncontrolled or whose control, in the opinion of the Investigator,
             may be jeopardized by participation in this study or by the complications of this
             therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sreenivas Kumar, MD, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Care Hospital, Hyderabad</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Satya Gupta</last_name>
    <role>Principal Investigator</role>
    <affiliation>SAL Hospital, Ahmedabad</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R Keshava, MD, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bhagwan Mahaveer JAin Hospital, Bangalore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prakash VS, MD., DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>MS Ramaiah Memorial Hospital, Bangalore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Care Hospital</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SAL Hospital and Medical Institute</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MS Ramaiah Memorial Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhagawan Mahaveer Jain Heart Centre</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>5660052</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2009</study_first_submitted>
  <study_first_submitted_qc>April 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2009</study_first_posted>
  <last_update_submitted>March 4, 2013</last_update_submitted>
  <last_update_submitted_qc>March 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mesenchymal stem cells</keyword>
  <keyword>myocardial infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plasma-lyte 148</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

